tiprankstipranks
Trending News
More News >
RaySearch Laboratories AB Class B (SE:RAY.B)
:RAY.B

RaySearch Laboratories AB (RAY.B) Price & Analysis

Compare
1 Followers

RAY.B Stock Chart & Stats

kr219.00
-kr6.00(-2.45%)
At close: 4:00 PM EST
kr219.00
-kr6.00(-2.45%)

RaySearch Laboratories AB News

RAY.B FAQ

What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest stock price was kr178.00 and its highest was kr373.50 in the past 12 months.
    What is RaySearch Laboratories AB Class B’s market cap?
    RaySearch Laboratories AB Class B’s market cap is kr6.61B.
      When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
      RaySearch Laboratories AB Class B’s upcoming earnings report date is Apr 29, 2026 which is in 75 days.
        How were RaySearch Laboratories AB Class B’s earnings last quarter?
        Currently, no data Available
        Is RaySearch Laboratories AB Class B overvalued?
        According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does RaySearch Laboratories AB Class B pay dividends?
          RaySearch Laboratories AB Class B pays a Annually dividend of kr3 which represents an annual dividend yield of 1.32%. See more information on RaySearch Laboratories AB Class B dividends here
            What is RaySearch Laboratories AB Class B’s EPS estimate?
            RaySearch Laboratories AB Class B’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does RaySearch Laboratories AB Class B have?
            RaySearch Laboratories AB Class B has 30,799,536 shares outstanding.
              What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
              Currently, no hedge funds are holding shares in SE:RAY.B
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Company Description

                RaySearch Laboratories AB Class B

                RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.

                RaySearch Laboratories AB (RAY.B) Earnings & Revenues

                RAY.B Company Deck

                RAY.B Earnings Call

                Q4 2026
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The call presents a broadly positive operational and commercial picture: record revenues, strong organic growth, improving profitability and cash position, significant clinical milestones and substantial AI adoption/use cases. Key negatives are material currency headwinds, a book-to-bill ratio below 1 and slower-than-desired traction for RayCare (partly tied to regulatory timing). Management expects margin improvement (target at least 25% for 2026) and a RayCare ramp in coming years, and has strengthened shareholder returns with a higher dividend and a 50% payout policy.View all SE:RAY.B earnings summaries
                Similar Stocks
                Company
                Price & Change
                Follow
                Elekta AB
                Saniona AB
                C-Rad AB Class B
                Vicore Pharma Holding AB
                MedCap AB

                Options Prices

                Currently, No data available
                ---
                Popular Stocks